Lack of almagate interference in breath test results for Helicobacter pylori diagnosis (Almatest study).

Ausencia de interferencia de almagato en los resultados de la prueba de aliento para el diagnóstico de Helicobacter pylori (estudio Almatest).

Journal

Gastroenterologia y hepatologia
ISSN: 0210-5705
Titre abrégé: Gastroenterol Hepatol
Pays: Spain
ID NLM: 8406671

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 09 07 2020
revised: 05 10 2020
accepted: 22 10 2020
pubmed: 29 11 2020
medline: 4 2 2022
entrez: 28 11 2020
Statut: ppublish

Résumé

The Observational, multicentre study in adult patients treated with almagate in whom a UBT (TAUKIT®) was indicated. When the UBT result was negative, use of almagate was stopped for 30 days and the UBT was repeated. When the result was positive, no further determinations were made. The primary endpoint was the percentage of patients who, having had a negative result in the first breath test, were positive in the second after having stopped taking almagate (UBT false negatives, possibly attributable to almagate). Of the 167 evaluable patients, 59% were female, average age was 49 and 97% had gastrointestinal symptoms. The result of the first UBT was negative in 71% of cases. Of these, in the second UBT test after stopping the almagate, the negative result was confirmed in 97.5%. Out of the total number of cases evaluated, the rate of false negatives was 1.8%. Taking almagate has minimal or no interference in the result of UBT for the diagnosis of H. pylori infection. It can therefore be used in the weeks prior to a UBT.

Identifiants

pubmed: 33248174
pii: S0210-5705(20)30446-5
doi: 10.1016/j.gastrohep.2020.10.016
pii:
doi:

Substances chimiques

Antacids 0
Carbon Isotopes 0
Carbonates 0
almagate 568Z59H7ZJ
Aluminum Hydroxide 5QB0T2IUN0
Urea 8W8T17847W
Magnesium Hydroxide NBZ3QY004S

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

628-636

Informations de copyright

Copyright © 2021 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

Auteurs

Carles Pons (C)

Instituto de Investigación Biomédica de Bellvitge (IDIBELL), Hospital de Viladecans, Barcelona, España. Electronic address: cpvilardell.hv@gencat.cat.

Modesto Varas (M)

Hospital CIMA Sanitas, Barcelona, España.

Javier P Gisbert (JP)

Instituto de Investigación Sanitaria Princesa (IIS-IP), Hospital Universitario de La Princesa, Universidad Autónoma de Madrid, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, España.

Mercè Barenys (M)

Centro Médico Teknon, Barcelona, España.

Francesca Pajuelo (F)

Compañía farmacéutica Almirall, S.A., Barcelona, España.

Francisco Javier Fernández (FJ)

Compañía farmacéutica Almirall, S.A., Barcelona, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH